What Actually Happens During a Stem Cell Infusion? A Step-by-Step Guide

For most newcomers, “stem cell infusion” conjures a vague image of a bag of mysterious cells dripping into an arm. In reality, getting cells from a source (a patient's own bone marrow, fat tissue, or a donated umbilical cord) into a patient's bloodstream involves several distinct physical steps, each with its own setting, sensations, and timeline. This article walks through what actually happens, in order: how cells are sourced, how they're processed in a lab, how they're delivered back into the body, what patients typically feel during and after, and how monitoring and follow-up are handled. Because protocols differ significantly by clinic, by whether the source is the patient's own tissue (autologous) or a donor's (allogeneic), and by whether the treatment is part of a regulated clinical trial or an off-label commercial offering, this is a description of the general process rather than a single fixed script — and it's worth remembering that, aside from cord-blood-derived stem cells used for blood disorders, most stem cell infusions offered for other conditions are not FDA-approved uses, so patients should always confirm the specifics of their own protocol with their provider.

Step 1: Sourcing the Cells

The physical experience of “having cells taken” depends entirely on the source. If the treatment is autologous, the patient typically undergoes one of two outpatient procedures: a bone marrow aspiration, in which a needle is inserted into the posterior iliac crest (hip bone) under local anesthesia to draw liquid marrow, or a mini-liposuction, in which a small (roughly 2mm) incision is made and a cannula removes a modest volume of fat tissue under local (often tumescent) anesthesia. Both are same-day procedures; bone marrow aspiration can cause brief, sharp pressure as the needle penetrates the periosteum (the sensitive membrane covering the bone), while liposuction harvesting is usually described as similar to a “mini lipo” with mild soreness afterward that resolves in a few days. If the treatment is allogeneic, no procedure happens to the patient at all on this end — the cells came from a screened donor's umbilical cord tissue or cord blood, collected non-invasively at a prior birth and stored or processed by a tissue bank.

Step 2: Lab Processing

Once collected, raw tissue isn't ready for infusion. Bone marrow or blood-derived material is typically run through an apheresis machine, which separates and concentrates the stem cell fraction while returning the remaining blood components. Fat tissue is enzymatically or mechanically processed to isolate the stem cell-containing fraction. In many clinical protocols, especially those using donor-derived cells, this raw isolate is then expanded — cultured in a lab for days to weeks to multiply the cell count to a usable dose — within a cGMP (current Good Manufacturing Practice) compliant facility that follows sterility and quality-control standards. Cells intended for later use are often cryopreserved (frozen) in a solution containing a preservative called DMSO until the infusion date.

Step 3: The Delivery Method — IV Infusion vs. Injection

On treatment day, cells reach the target tissue one of two ways. IV infusion delivers the cell suspension into the bloodstream through a standard intravenous line, allowing cells to circulate systemically; this is the more common route for conditions affecting whole organ systems. Direct injection places cells at a specific damage site — a joint, tendon, or localized area — using a needle, sometimes with imaging guidance. Reported IV infusion times vary by protocol: some published mesenchymal stem cell trials report roughly one hour for a single dose delivered by drip, while some clinic-reported protocols describe a slower manual push of about 1 mL per minute over two to three hours. If cells were frozen, they are typically thawed and, depending on the facility's protocol, may be infused shortly after thawing or first “washed” to remove residual DMSO.

Step 4: What Patients Typically Experience

Most patients receive premedication — commonly an antihistamine and sometimes acetaminophen — roughly 30 to 60 minutes beforehand to reduce the chance of an infusion reaction. During the infusion itself, patients are usually awake, seated or reclined, and can often read, talk, or rest normally. A distinctive and well-documented sensation with cryopreserved cell products is a transient garlic-like or metallic taste in the mouth and a similar body odor afterward (from residual DMSO), which typically fades within about 48 hours; sucking on hard candy or citrus can help. Other commonly reported effects include mild throat tickling, transient low-grade fever, chills, fatigue, or soreness at the injection or infusion site — generally described in published safety data as short-lived and non-severe. Bone marrow or liposuction harvesting sites are separately sore for a few days but heal quickly.

Step 5: Monitoring During and After

Because an infusion reaction, while uncommon, can occur, nurses or clinicians routinely check vital signs throughout the infusion and remain in the room. After the infusion ends, protocols in published studies commonly describe an observation period of roughly 30 minutes to a few hours before discharge, sometimes followed by a phone check-in the next day to screen for delayed complications. Clinical trial data on IV mesenchymal stem cell infusions have generally reported low rates of serious adverse events, with most reactions being mild and self-limited, though safety monitoring standards and follow-up length vary by site and by whether the treatment is investigational.

Step 6: Recovery and Follow-Up Timeline

For most outpatient stem cell infusions or injections used outside of cancer treatment, patients go home the same day, sometimes within one to two hours of finishing. This is different from a full hematopoietic (blood-forming) stem cell transplant used in cancer care, which typically requires hospitalization while the body “engrafts” the new cells over roughly two to five weeks — a distinct and more intensive process from the outpatient MSC infusions discussed here. For the outpatient infusions covered in this article, clinics vary widely in how they schedule follow-up: some rely on a single infusion, others schedule repeat sessions weeks or months apart, and imaging or symptom check-ins are used to track response over the following weeks to months.

Bottom Line

A stem cell infusion is not a single standardized event but a multi-step process — sourcing, lab processing, delivery, monitoring, and follow-up — that looks somewhat different depending on the cell source, the clinic, and whether the treatment is investigational or offered commercially. Physically, most patients can expect a same-day outpatient visit, an IV drip or targeted injection lasting anywhere from about one to three hours, mild and short-lived side effects such as fatigue or a metallic taste, and a brief monitoring period before going home. What doesn't vary is the importance of asking questions: because protocols differ widely across clinics and because most stem cell infusions for conditions outside of blood disorders remain outside FDA approval, patients should ask their specific provider exactly what cell source, processing method, dose, and monitoring plan their own treatment involves.